Literature DB >> 9881865

Co-localization of P450 enzymes in the rat substantia nigra with tyrosine hydroxylase.

P M Watts1, A G Riedl, D C Douek, R J Edwards, A R Boobis, P Jenner, C D Marsden.   

Abstract

Susceptibility to develop Parkinson's disease has been linked to abnormalities of P450 enzyme function. Multiple P450 enzymes are expressed in brain but the relationship of these to Parkinson's disease is unknown. We have investigated the expression of P450 enzymes in the rat substantia nigra and their co-localization in tyrosine hydroxylase-positive neurons and astrocytes. Immunohistochemistry was performed using anti-peptide antisera against the following P450 enzymes: CYP1A1, CYP1A2, CYP2B1/2, CYP2C12, CYP2C13/2C6, CYP2D1, CYP2D4, CYP2E1, CYP3A1, CYP3A2 and NADPH-P450 oxidoreductase. Immunoreactivity in nigral cells was found only for CYP2E1 and CYP2C13/2C6. CYP2E1 immunoreactivity was localized to many midbrain nuclei including the substantia nigra pars compacta but not the substantia nigra pars reticulata while immunoreactivity to CYP2C13/2C6 was found in the substantia nigra pars compacta, substantia nigra pars reticulata and many other midbrain nuclei. Sections of rat midbrain double labelled for either CYP2E1 or CYP2C13/2C6 and tyrosine hydroxylase or glial fibrillary acidic protein were examined for co-localization by confocal laser scanning microscopy. CYP2E1 and CYP2C13/2C6 immunoreactivity was found in tyrosine hydroxylase-positive neurons in the substantia nigra pars compacta but not in glial cells. CYP2C13/2C6, but not CYP2E1, was also found in non-glial, non-tyrosine hydroxylase-expressing cells in the substantia nigra pars reticulata. Isoniazid induction increased CYP2E1 fluorescence signal intensity from nigral dopaminergic neurons. At least two P450 enzymes are found in nigral dopamine containing cells and one, namely CYP2E1, is selectively localized to this cell population. CYP2E1 is a potent generator of free radicals which may contribute to nigral pathology in Parkinson's disease. The expression of CYP2E1 in dopaminergic neurons in substantia nigra raises the possibility of a causal association with Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9881865     DOI: 10.1016/s0306-4522(97)00649-0

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  19 in total

Review 1.  Drug-metabolizing cytochrome P450s in the brain.

Authors:  Sharon L Miksys; Rachel F Tyndale
Journal:  J Psychiatry Neurosci       Date:  2002-11       Impact factor: 6.186

2.  Cytochrome P450 2D6 enzyme neuroprotects against 1-methyl-4-phenylpyridinium toxicity in SH-SY5Y neuronal cells.

Authors:  Amandeep Mann; Rachel F Tyndale
Journal:  Eur J Neurosci       Date:  2010-03-22       Impact factor: 3.386

3.  HIV-1 Tat protein promotes neuronal dysfunction through disruption of microRNAs.

Authors:  J Robert Chang; Ruma Mukerjee; Asen Bagashev; Luis Del Valle; Tinatin Chabrashvili; Brian J Hawkins; Johnny J He; Bassel E Sawaya
Journal:  J Biol Chem       Date:  2011-09-28       Impact factor: 5.157

4.  APOE and CYP2E1 polymorphisms, alcohol consumption, and Parkinson's disease in a Japanese population.

Authors:  Chikako Kiyohara; Yoshihiro Miyake; Midori Koyanagi; Takahiro Fujimoto; Senji Shirasawa; Keiko Tanaka; Wakaba Fukushima; Satoshi Sasaki; Yoshio Tsuboi; Tatsuo Yamada; Tomoko Oeda; Takami Miki; Nobutoshi Kawamura; Nobutaka Sakae; Hidenao Fukuyama; Yoshio Hirota; Masaki Nagai
Journal:  J Neural Transm (Vienna)       Date:  2011-03-01       Impact factor: 3.575

5.  Contrasting antioxidant and cytotoxic effects of peroxiredoxin I and II in PC12 and NIH3T3 cells.

Authors:  S Simzar; R Ellyin; H Shau; T A Sarafian
Journal:  Neurochem Res       Date:  2000-12       Impact factor: 3.996

6.  Sex hormones regulate cerebral drug metabolism via brain miRNAs: down-regulation of brain CYP2D by androgens reduces the analgesic effects of tramadol.

Authors:  Jie Li; Mengmeng Xie; Xiaoshuang Wang; Xiufang Ouyang; Yu Wan; Guicheng Dong; Zheqiong Yang; Jing Yang; Jiang Yue
Journal:  Br J Pharmacol       Date:  2015-08-26       Impact factor: 8.739

Review 7.  Solvents and Parkinson disease: a systematic review of toxicological and epidemiological evidence.

Authors:  Edward A Lock; Jing Zhang; Harvey Checkoway
Journal:  Toxicol Appl Pharmacol       Date:  2012-12-07       Impact factor: 4.219

Review 8.  Cytochrome P450-mediated estrogen catabolism therapeutic avenues in epilepsy.

Authors:  Megha Gautam; Ganesh Thapa
Journal:  Acta Neurol Belg       Date:  2020-08-02       Impact factor: 2.396

9.  Cytochrome P450 2E1 gene polymorphisms/haplotypes and Parkinson's disease in a Swedish population.

Authors:  H Niazi Shahabi; L Westberg; J Melke; A Håkansson; A Carmine Belin; O Sydow; L Olson; B Holmberg; H Nissbrandt
Journal:  J Neural Transm (Vienna)       Date:  2009-04-21       Impact factor: 3.575

10.  Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment.

Authors:  Amandeep Mann; Sharon Miksys; Anna Lee; Deborah C Mash; Rachel F Tyndale
Journal:  Neuropharmacology       Date:  2008-07-19       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.